Desflurane-induced Myocardial Protection

Desflurane-induced Myocardial Protection in Aortic Valve Surgery: A Pilot Study

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02019797

Enrollment

Registered

2013-12-24

Start date

2014-01-31

Completion date

2016-12-31

Last updated

2013-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis

Keywords

aortic valve replacement

Brief summary

This study examines pharmacological preconditioning and post conditioning of desflurane by comparing cardiac troponin release in patients receiving either desflurane or propofol for the aortic valve surgery.

Detailed description

Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass are included in the study. Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a TIVA during the surgery. All patients receive a continuous infusion of remifentanil. Biomarker of myocardial damage troponin I is examined at 4 points; T1: after the induction of anesthesia, T2: arrival at ICU, T3: 12 hours after the ICU arrival, T4: 24 hours after the ICU arrival, T5: third post operative day (3POD).

Interventions

DRUGDesflurane

Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass.

Exclusion criteria

* Patients younger than 20 years old. * Recent myocardial infarction (within 1 year). * Renal dysfunction (GFR less than 50ml/min). * Known allergy to study drugs including propofol.

Design outcomes

Primary

Measure	Time frame
Troponin I	up to 3 days

Secondary

Measure	Time frame
Length of ICU stay, Length of hospital stay	up to 2 months after the surgery
Acute myocardial infarction	up to 7 days

Countries

Japan

Contacts

Primary ContactNobuyuki Katori, M.D.

nbyk@a5.keio.jp81-3-3353-1211

Backup ContactHiroshi Morisaki, M.D.

morisaki@z8.keio.jp81-3-3353-1211

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026